Weighing Bariatric Surgery Costs, Benefits, and Risks in NASH Cirrhosis Patients (CME/CE)
(MedPage Today) -- Could be cost-effective in NASH with compensated cirrhosis, modeling study suggests
Conclusions: The 30-day readmission rate in patients with AH was high and stable during the study period. Factors associated with readmission may be helpful for development of consensus-based expert guidelines, treatment algorithms, and policy changes to help decrease readmission in AH.
Publication date: Available online 16 September 2019Source: The American Journal of SurgeryAuthor(s): Minyoung Kwak, J. Hunter Mehaffey, Robert B. Hawkins, Angel Hsu, Bruce Schirmer, Peter T. HallowellAbstractIntroductionObesity is a risk factor for non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Bariatric surgery can provide durable weight-loss, but little is known about the later development of NASH and HCC after surgery.MethodsBariatric surgery (n=3,410) and obese controls (n=46,873) from an institutional data repository were propensity score matched 1:1 by demographics, comorbidities, BMI, and ...
CONCLUSION: Treatment of chronic HCV with DAAs was associated with increased body mass index. Further studies are needed to explore if this effect is secondary to treatment with DAAs or is an improvement in the liver function and lifestyle of treated patients. PMID: 31418415 [PubMed - in process]
ConclusionDespite relatively stable trends in AH-related readmission, the total LOS and cost has been rising. A target-directed approach with a focus on high-risk subpopulations may help understand the unique challenges associated with the rising cost of AH-related readmissions.
Over the past 10 years bariatric surgeons have embraced our role in not only producing sustained and long-term weight loss, but more importantly we have embraced our role in improving metabolic conditions, such as nonalcoholic fatty liver disease (NAFLD). With obesity increasing worldwide we have seen a concomitant increase in the number of patients who progress from NAFLD to nonalcoholic steatohepatitis (NASH) and ultimately cirrhosis . Although we have increasing evidence of remission of NAFLD and NASH, the liver biopsy remains the gold standard for tracking regression and remission.
Over the past 10 years bariatric surgeons have embraced our role in not only producing sustained and long-term weight loss, but more importantly we have embraced our role in improving metabolic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD). With obesity increasing worldwide we have seen a concomitant increase in patients with the progression of NAFLD to nonalcoholic steatohepatitis (NASH) and ultimately cirrhosis . Although we have more and more evidence of remission of NAFLD and NASH, liver biopsy remains the gold standard for tracking regression and remission.
This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p
Conclusions: While there is a certain overlap between the results of the current study and published transcriptomic profiles of non-transplanted livers with steatosis, we have identified discrete characteristics of the non-alcoholic fatty liver disease in liver grafts potentially utilizable for the establishment of predictive signature. Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized countries, its prevalence being estimated at 19–31.3% (1). It encompasses a range of conditions that are thought to arise from fatty liver (simple steatosis) throu...
ConclusionsOur study not only confirms the significant association of NAFLD with obesity but also outlines a simple non-invasive scoring system to identify obese individuals at high risk for NASH.
Alexandra Neyazi1†, Vanessa Buchholz1†, Alexandra Burkert1, Thomas Hillemacher1,2, Martina de Zwaan3, Wolfgang Herzog4, Kirsten Jahn1, Katrin Giel5, Stephan Herpertz6, Christian A. Buchholz1, Andreas Dinkel7, Markus Burgmer8, Almut Zeeck9, Stefan Bleich1, Stephan Zipfel5† and Helge Frieling1*† 1Molecular Neuroscience Laboratory, Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany 2Department of Psychiatry and Psychotherapy, Paracelsus Medizinische Privatuniversität Nürnberg, Nuremberg, Germany 3Department of Psychos...